PMID- 34575870
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 18
DP  - 2021 Sep 8
TI  - Building Personalized Cancer Therapeutics through Multi-Omics Assays and 
      Bacteriophage-Eukaryotic Cell Interactions.
LID - 10.3390/ijms22189712 [doi]
LID - 9712
AB  - Bacteriophage-eukaryotic cell interaction provides the biological foundation of 
      Phage Display technology, which has been widely adopted in studies involving 
      protein-protein and protein-peptide interactions, and it provides a direct link 
      between the proteins and the DNA encoding them. Phage display has also 
      facilitated the development of new therapeutic agents targeting personalized 
      cancer mutations. Proteins encoded by mutant genes in cancers can be processed 
      and presented on the tumor cell surface by human leukocyte antigen (HLA) 
      molecules, and such mutant peptides are called Neoantigens. Neoantigens are 
      naturally existing tumor markers presented on the cell surface. In clinical 
      settings, the T-cell recognition of neoantigens is the foundation of cancer 
      immunotherapeutics. This year, we utilized phage display to successfully develop 
      the 1st antibody-based neoantigen targeting approach for next-generation 
      personalized cancer therapeutics. In this article, we discussed the strategies 
      for identifying neoantigens, followed by using phage display to create 
      personalized cancer therapeutics-a complete pipeline for personalized cancer 
      treatment.
FAU - Wang, Qing
AU  - Wang Q
AUID- ORCID: 0000-0002-7979-766X
AD  - Complete Omics Inc., 1448 S. Rolling Rd, Baltimore, MD 21227, USA.
LA  - eng
GR  - 202102668/0cancer Research Fund/
PT  - Journal Article
PT  - Review
DEP - 20210908
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antigens)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptide Library)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens/*chemistry
MH  - Antigens, Neoplasm/metabolism
MH  - Bacteriophages/*metabolism
MH  - Cancer Vaccines/immunology/metabolism
MH  - Drug Design
MH  - Eukaryotic Cells/*metabolism
MH  - HLA Antigens/chemistry
MH  - Humans
MH  - Immunotherapy
MH  - Medical Oncology/trends
MH  - Mutation
MH  - Neoplasms/*genetics/*therapy
MH  - Peptide Library
MH  - Peptides/metabolism
MH  - Precision Medicine/*trends
MH  - T-Lymphocytes/immunology
PMC - PMC8468737
OTO - NOTNLM
OT  - cancer vaccine
OT  - immunotherapeutic
OT  - neoantigen
OT  - personalized cancer treatment
OT  - phage display
COIS- Q.W. is the founder and CEO of and has ownership interest (including patents) in 
      Complete Omics Inc. located at Baltimore Maryland.
EDAT- 2021/09/29 06:00
MHDA- 2021/11/16 06:00
PMCR- 2021/09/08
CRDT- 2021/09/28 01:17
PHST- 2021/08/04 00:00 [received]
PHST- 2021/08/31 00:00 [revised]
PHST- 2021/09/01 00:00 [accepted]
PHST- 2021/09/28 01:17 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2021/09/08 00:00 [pmc-release]
AID - ijms22189712 [pii]
AID - ijms-22-09712 [pii]
AID - 10.3390/ijms22189712 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Sep 8;22(18):9712. doi: 10.3390/ijms22189712.